Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes

Alan Rodney, Pauline Dieringer, Paul Mathew, Eric Jonasch, Nizar Tannir, Lance C. Pagliaro

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

BACKGROUND. The primary objective of the current study was to evaluate the effectiveness of capecitabine and gemcitabine in the treatment of patients with androgen-independent prostate cancer (AIPCa) who experienced disease progression after taxane therapy. The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients. METHODS, Patients with AIPCa, either metastatic or unresectable disease, and prior taxane therapy were eligible. Patients were treated with 800 mg/m2 of capecitabine orally twice daily (1600 mg/m2 per day) for 14 days, and 800 mg/m2 of gemcitabine intravenously on Days 1 and 8. This regimen was repeated every 21 days. Response to therapy was determined by measuring prostate-specific antigen concentration. RESULTS. Sixteen patients participated in this study from June 2003 to January 2004. There were no responses as defined by a 50% decline in prostate-specific antigen. The study was terminated early because the response rate was not projected to exceed 30% (rejection error of 10%). Toxicities were notable: 3 patients had Grade 3 thrombocytopenia, 4 patients had Grade 3 neutropenia, and 3 patients had Grade 3 infections (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Eight patients (50%) required dose reduction or treatment interruption. CONCLUSIONS. The combination of capecitabine and gemcitabine for the salvage treatment of patients with AIPCa was associated with significant toxicities and was ineffective for induction of disease regression.

Original languageEnglish (US)
Pages (from-to)2143-2147
Number of pages5
JournalCancer
Volume106
Issue number10
DOIs
StatePublished - May 15 2006
Externally publishedYes

Fingerprint

gemcitabine
Taxoids
Androgens
Prostatic Neoplasms
Therapeutics
Prostate-Specific Antigen
Capecitabine
Salvage Therapy
National Cancer Institute (U.S.)

Keywords

  • Androgen-independent
  • Capecitabine
  • Gemcitabine
  • Phase II clinical trial
  • Prostate carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. / Rodney, Alan; Dieringer, Pauline; Mathew, Paul; Jonasch, Eric; Tannir, Nizar; Pagliaro, Lance C.

In: Cancer, Vol. 106, No. 10, 15.05.2006, p. 2143-2147.

Research output: Contribution to journalArticle

Rodney, Alan ; Dieringer, Pauline ; Mathew, Paul ; Jonasch, Eric ; Tannir, Nizar ; Pagliaro, Lance C. / Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. In: Cancer. 2006 ; Vol. 106, No. 10. pp. 2143-2147.
@article{a02faf1db2eb472fac45fccd9d1aebfe,
title = "Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes",
abstract = "BACKGROUND. The primary objective of the current study was to evaluate the effectiveness of capecitabine and gemcitabine in the treatment of patients with androgen-independent prostate cancer (AIPCa) who experienced disease progression after taxane therapy. The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients. METHODS, Patients with AIPCa, either metastatic or unresectable disease, and prior taxane therapy were eligible. Patients were treated with 800 mg/m2 of capecitabine orally twice daily (1600 mg/m2 per day) for 14 days, and 800 mg/m2 of gemcitabine intravenously on Days 1 and 8. This regimen was repeated every 21 days. Response to therapy was determined by measuring prostate-specific antigen concentration. RESULTS. Sixteen patients participated in this study from June 2003 to January 2004. There were no responses as defined by a 50{\%} decline in prostate-specific antigen. The study was terminated early because the response rate was not projected to exceed 30{\%} (rejection error of 10{\%}). Toxicities were notable: 3 patients had Grade 3 thrombocytopenia, 4 patients had Grade 3 neutropenia, and 3 patients had Grade 3 infections (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Eight patients (50{\%}) required dose reduction or treatment interruption. CONCLUSIONS. The combination of capecitabine and gemcitabine for the salvage treatment of patients with AIPCa was associated with significant toxicities and was ineffective for induction of disease regression.",
keywords = "Androgen-independent, Capecitabine, Gemcitabine, Phase II clinical trial, Prostate carcinoma",
author = "Alan Rodney and Pauline Dieringer and Paul Mathew and Eric Jonasch and Nizar Tannir and Pagliaro, {Lance C.}",
year = "2006",
month = "5",
day = "15",
doi = "10.1002/cncr.21894",
language = "English (US)",
volume = "106",
pages = "2143--2147",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes

AU - Rodney, Alan

AU - Dieringer, Pauline

AU - Mathew, Paul

AU - Jonasch, Eric

AU - Tannir, Nizar

AU - Pagliaro, Lance C.

PY - 2006/5/15

Y1 - 2006/5/15

N2 - BACKGROUND. The primary objective of the current study was to evaluate the effectiveness of capecitabine and gemcitabine in the treatment of patients with androgen-independent prostate cancer (AIPCa) who experienced disease progression after taxane therapy. The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients. METHODS, Patients with AIPCa, either metastatic or unresectable disease, and prior taxane therapy were eligible. Patients were treated with 800 mg/m2 of capecitabine orally twice daily (1600 mg/m2 per day) for 14 days, and 800 mg/m2 of gemcitabine intravenously on Days 1 and 8. This regimen was repeated every 21 days. Response to therapy was determined by measuring prostate-specific antigen concentration. RESULTS. Sixteen patients participated in this study from June 2003 to January 2004. There were no responses as defined by a 50% decline in prostate-specific antigen. The study was terminated early because the response rate was not projected to exceed 30% (rejection error of 10%). Toxicities were notable: 3 patients had Grade 3 thrombocytopenia, 4 patients had Grade 3 neutropenia, and 3 patients had Grade 3 infections (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Eight patients (50%) required dose reduction or treatment interruption. CONCLUSIONS. The combination of capecitabine and gemcitabine for the salvage treatment of patients with AIPCa was associated with significant toxicities and was ineffective for induction of disease regression.

AB - BACKGROUND. The primary objective of the current study was to evaluate the effectiveness of capecitabine and gemcitabine in the treatment of patients with androgen-independent prostate cancer (AIPCa) who experienced disease progression after taxane therapy. The secondary objective was to evaluate the safety and tolerability of the combination of capecitabine and gemcitabine in these patients. METHODS, Patients with AIPCa, either metastatic or unresectable disease, and prior taxane therapy were eligible. Patients were treated with 800 mg/m2 of capecitabine orally twice daily (1600 mg/m2 per day) for 14 days, and 800 mg/m2 of gemcitabine intravenously on Days 1 and 8. This regimen was repeated every 21 days. Response to therapy was determined by measuring prostate-specific antigen concentration. RESULTS. Sixteen patients participated in this study from June 2003 to January 2004. There were no responses as defined by a 50% decline in prostate-specific antigen. The study was terminated early because the response rate was not projected to exceed 30% (rejection error of 10%). Toxicities were notable: 3 patients had Grade 3 thrombocytopenia, 4 patients had Grade 3 neutropenia, and 3 patients had Grade 3 infections (according to the National Cancer Institute Common Toxicity Criteria [version 2.0]). Eight patients (50%) required dose reduction or treatment interruption. CONCLUSIONS. The combination of capecitabine and gemcitabine for the salvage treatment of patients with AIPCa was associated with significant toxicities and was ineffective for induction of disease regression.

KW - Androgen-independent

KW - Capecitabine

KW - Gemcitabine

KW - Phase II clinical trial

KW - Prostate carcinoma

UR - http://www.scopus.com/inward/record.url?scp=33646373451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646373451&partnerID=8YFLogxK

U2 - 10.1002/cncr.21894

DO - 10.1002/cncr.21894

M3 - Article

C2 - 16598751

AN - SCOPUS:33646373451

VL - 106

SP - 2143

EP - 2147

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -